Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28. Februar 2022 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the UBS Global Healthcare Virtual Conference
20. Mai 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...